慢性免疫性血小板減少性紫外線における血小板の産生を刺激する新世代の薬
Alan T Nurden1, Jean-François Viallard, Paquita Nurden
1French National Reference Centre for Platelet Disorders, Hôpital Xavier Arnozan, Pessac, France. alan.nurden@cnrshl.u-bordeaux2.fr
Lancet (London, England)
|March 28, 2009
まとめ
Idiopathic thrombocytopenic purpura (ITP) は,既得自己免疫疾患である. 既得自己免疫疾患である. 既得自己免疫疾患である. 既得自己免疫疾患である. 既得自己免疫疾患である. 既得自己免疫疾患である. エルトロンボパグやロミプラスティムのようなトロンボポエチン受容体アゴニストは,耐性ITP患者における血小板数の増加に有望であることが示されています.
科学分野:
- 血液学 ヘマトロジ
- 免疫学 免疫学とは
- 薬理学 薬理学とは
背景:
- Idiopathic thrombocytopenic purpura (ITP) は,血小板数が低いことを特徴とする既得自己免疫疾患である.
- 主な原因は自己抗体の発生であり,潜在的に生命を脅かす出血につながる可能性があります.
- 従来の免疫抑制療法では,疾患の異質性により効果が低下することがあります.
研究 の 目的:
- 慢性性イディオパシー性血栓塞栓性紫毛症の代替治療戦略をレビューする.
- 新型トロンボポエチン受容体アゴニストの有効性と安全性を評価する.
主な方法:
- イディオパシー性トランボサイトペニック紫毛症の治療に関する現在の文献のレビュー.
- 第2世代トロンボポエチン受容体アゴニストの臨床試験データの分析.
主要な成果:
- トロンボポエチン受容体アゴニストなどのメガカリオサイトを刺激する新開発された薬剤は,代替戦略を提供します.
- エルトロンボパグとロミプロスティムは,耐火性ITP患者の血小板生成を安全に増加させ,維持する能力を示しています.
- 第2世代のアゴニストは,以前の同類剤で見られた不良免疫反応を克服し,有望に思える.
結論:
- エルトロンボパグとロミプロスティムは,耐火性イディオパシー性血栓縮性紫外線に対する有望な治療法である.
- 長期的な副作用の評価は現在進行中です.
- 慢性ITPの総合的な管理におけるこれらのエージェントの正確な役割は,さらに確立する必要があります.
関連する概念動画
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Structure and Function of Platelets
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...